Synthaverse

Synthaverse EBIT Margin

The EBIT Margin (Operating Margin) of Synthaverse (SVE.WA) as of Oct 18, 2026 is -48.98 %. In the previous year, EBIT Margin (Operating Margin) was 17.32 % — a change of -382.86% (lower).

EBIT Margin

-48.98 %

YoY

-382.86%

Last updated:

EBIT Margin (Operating Margin) of Synthaverse is 2025 -48.98 % . EBIT Margin (Operating Margin) of Synthaverse was 2024 17.32 % . It decreases by -382.86% lower compared to the previous year.

Synthaverse's operating (EBIT) margin stands at -49.0%, down from 17.5% several years earlier.

The Synthaverse EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
-109.74 PLN
Jan 1, 2019
14.62 PLN
Jan 1, 2020
14.76 PLN
Jan 1, 2021
17.48 PLN
Jan 1, 2022
19.53 PLN
Jan 1, 2023
14.75 PLN
Jan 1, 2024
17.32 PLN
Jan 1, 2025
-48.98 PLN
The Synthaverse EBIT Margin history
YEAREBIT MarginYoY
-48.98 %-382.86%
17.32 %+17.37%
14.75 %-24.47%
19.53 %+11.78%
17.48 %+18.43%
14.76 %+0.92%
14.62 %-113.32%
-109.74 %-810.00%
15.46 %-120.21%
-76.47 %-2.05%
-78.07 %-965.07%
9.03 %+5,739.82%
0.15 %-163.56%
-0.24 %-447.58%
0.07 %-53.89%
0.15 %+71.29%
0.09 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Synthaverse Stock analysis

What does Synthaverse do? Biomed Lublin is a Polish company that has been active in the production of serums and vaccines since 1950. It has grown to become a leading producer of biological substances and medical devices in Eastern Europe. The company was originally a state institution for the development of animal vaccines but was privatized after the political changes in the late 1980s. Since 2002, it has been listed on the Warsaw Stock Exchange and has expanded its focus. Biomed Lublin operates in four main areas: veterinary medicine, human medicine, diagnostics, and laboratory equipment. It has a strong reputation in the veterinary medicine field, offering vaccines and diagnostics for livestock and pets. The company is also involved in human medicine, producing vaccines and diagnostics exclusively in Poland. In the diagnostics field, Biomed Lublin has developed and manufactured a variety of test kits used in medical diagnostics. It also offers laboratory equipment such as microscopes, pipettes, and centrifuges for medical and biological testing in hospitals and laboratories. Overall, Biomed Lublin aims to continue expanding its presence in the biotech industry in Eastern Europe and providing high-quality and effective diagnostic and therapeutic solutions to improve the health of both humans and animals. Synthaverse is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Synthaverse stock

EBIT Margin (Operating Margin) of Synthaverse is -48.98 % in 2025.

EBIT Margin (Operating Margin) of Synthaverse changed from 17.32 % to -48.98 %, representing a -382.86% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Synthaverse since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Synthaverse with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Synthaverse

All Key Metrics — Synthaverse